Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8470359 | TOLMAR THERAP | Sustained release polymer |
Oct, 2023
(8 months from now) |
Market Authorisation Date: 24 July, 2002
Treatment: Method of treating cancer
Dosage: POWDER;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US8470359 | TOLMAR | Sustained release polymer |
Oct, 2023
(8 months from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Indication (I) | May 1, 2023 |
Market Authorisation Date: 01 May, 2020
Treatment: Method of treating pediatric patients 2 years of age and older with central precocious puberty
Dosage: POWDER;SUBCUTANEOUS
Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8815801 | ABBVIE ENDOCRINE INC | Controlled release composition and method of producing the same |
Jun, 2022
(7 months ago) | |
US8921326 | ABBVIE ENDOCRINE INC | Sustained-release composition and method for producing the same |
Feb, 2031
(8 years from now) |
Market Authorisation Date: 22 December, 1995
Treatment: Palliative treatment of prostate cancer
Dosage: INJECTABLE;INJECTION
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic